- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07394790
Efectividad de un Programa de Prescripción de Ejercicio Físico en Atención Primaria para Adultos de 65 Años y Mayores: PREFIS-AP
Eficacia de un Programa de Prescripción de Ejercicio Físico en Atención Primaria para Mejorar la Condición Física y la Calidad de Vida en Adultos de 65 Años y Más en una Zona de Salud Rural: Ensayo Controlado Aleatorizado PREFIS-AP
This randomized controlled trial aims to evaluate the effectiveness of an individualized Physical Exercise Prescription Program delivered in Primary Care for adults aged 65 years and older. The intervention includes a structured assessment of physical fitness, muscle function and mass, physical activity level, and quality of life, followed by a tailored exercise plan encompassing aerobic, strength, respiratory, flexibility, and balance training. Outcomes will be compared with a control group receiving standard health advice to walk briskly for at least 30 minutes daily. The study also explores associations between polypharmacy, muscle function, physical performance, and quality of life.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Sedentary behavior is strongly associated with multiple adverse health outcomes, particularly in older adults. Conventional lifestyle advice alone has shown limited effectiveness in increasing physical activity levels. Exercise prescription delivered through structured evaluation, individualized planning, and scheduled follow-up may lead to clinically significant improvements in physical function and quality of life.
This study will recruit 210 adults aged ≥65 years from a rural Primary Care center. Participants will undergo baseline assessments including sociodemographic variables, anthropometric measures, muscle strength (handgrip dynamometry and chair stand test), aerobic capacity (6-minute walk test), muscle mass (calf circumference and ultrasound of rectus femoris), physical activity level (GPAQ), and quality of life (SF-36). After randomization (1:1), the intervention group will receive a personalized exercise prescription generated through the MEDORA Primary Care electronic system and supervised by a qualified Exercise Technician. The control group will receive routine health advice.
After three months, all participants will be reassessed using the same measures. The study will analyze the effect of the intervention on physical fitness, physical activity, muscle mass and function, and quality of life, including sex-specific differences and the role of polypharmacy. The project incorporates a partial masking strategy and uses REDCap for data management and anonymization.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Víctor Manuel González Rodríguez, MD
- Número de teléfono: 54196 +34923 356 677
- Correo electrónico: vmgonzalez@saludcastillayleon.es
Ubicaciones de estudio
-
-
Salamanca
-
Villoría, Salamanca, España, 37339
- Reclutamiento
- Centro de Salud de Villoria
-
Contacto:
- Víctor Manuel González Rodríguez, MD
- Número de teléfono: 54196 34 923 356 677
- Correo electrónico: vmgonzalez@saludcastillayleon.es
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 65 years
- Motivated to participate and able to provide informed consent
- Able to attend baseline assessment and follow-up
- Clinical stability allowing participation in exercise evaluation
Exclusion Criteria:
- Recent myocardial infarction
- Unstable angina
- Uncontrolled arrhythmias (symptomatic or hemodynamically compromising)
- Syncope
- Acute endocarditis, myocarditis, or pericarditis
- Severe or symptomatic aortic stenosis
- Uncontrolled heart failure
- Recent pulmonary thromboembolism or pulmonary infarction
- Lower-limb thrombosis
- Severe aortic stenosis or suspected dissecting aortic aneurysm
- Uncontrolled asthma
- Pulmonary edema
- Acute respiratory failure
- Acute non-cardiopulmonary illness that impairs exercise capacity (e.g., infection, thyrotoxicosis, acute renal failure)
- Mental disorder that prevents adequate cooperation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Physical Exercise Prescription Program
Participants receive a 12-week individualized multicomponent Exercise Prescription Programme integrated into routine Primary Care and supported by the MEDORA® electronic health record. Exercise prescription is based on baseline clinical and functional assessment and includes aerobic, resistance, balance and flexibility exercise, with respiratory muscle training when considered clinically indicated. Exercise is performed both independently at home and during supervised group reinforcement sessions available three days per week in municipal sports facilities. During supervised sessions, each participant follows his or her individualized exercise prescription rather than a uniform group exercise programme. Exercise type, intensity, duration, frequency and progression are individualized according to baseline clinical and functional status, tolerance and progression. |
Participants receive a structured and individualized 12-week program including: Aerobic exercise (continuous and interval training, intensity guided by Borg scale) Strength training using elastic bands (progressively increasing repetitions, series, and load) Respiratory exercises with pressure-based devices Flexibility exercises (static stretching routines) Balance training (single-leg stance, heel-toe walking, eyes-closed tasks) The program is generated through the MEDORA electronic system after baseline evaluation. A certified Exercise Technician provides instruction, supervision, and progression adjustments. Exercise type, intensity, duration, frequency and progression are individualized within the exercise-prescription framework according to baseline clinical and functional assessment |
|
Sin intervención: Standard Health Advice
Participants allocated to the control group receive usual Primary Care and general physical-activity advice consistent with World Health Organization recommendations. They do not receive an individualized structured exercise prescription, supervised reinforcement sessions, or intervention-specific follow-up. The study did not systematically prescribe control participants to walk briskly for at least 30 minutes per day. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Quality of Life
Periodo de tiempo: Baseline to 3 months.
|
Quality of Life will be measured by the SF-36 questionnaire. The SF-36 questionnaire is a widely used, patient-reported questionnaire measuring health-related quality of life. It uses points to assess health, with responses on Likert scales (e.g., 0 to 100) transformed into scores for 8 health domains: physical functioning, role limitations (physical/emotional), bodily pain, general health, vitality, social functioning, and mental health, where higher scores mean better health, ranging from 0 (maximum disability) to 100 (no disability). |
Baseline to 3 months.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Physical Activity Level (GPAQ)
Periodo de tiempo: Baseline to 3 months.
|
Change in physical activity level as measured by the Global Physical Activity Questionnaire (GPAQ), including time spent in work-related activity, transport-related activity, leisure-time activity, and sedentary behavior. Participants will be classified into WHO categories (high, moderate, or low/inactive) based on standardized scoring procedures. |
Baseline to 3 months.
|
|
Aerobic Capacity (6-Minute Walk Test)
Periodo de tiempo: Baseline to 3 months.
|
Change in functional aerobic capacity assessed by the 6-minute walk test (6MWT). The primary variable will be the total distance walked in meters during 6 minutes. Physiological responses (heart rate, oxygen saturation, perceived exertion using Borg scale) will also be recorded. |
Baseline to 3 months.
|
|
Muscle Strength - Handgrip Dynamometry
Periodo de tiempo: Baseline to 3 months.
|
Change in maximal isometric handgrip strength measured with a JAMAR dynamometer (kg), using the highest value from standardized bilateral measurements. Cut-off values will follow European sarcopenia consensus criteria (<27 kg for men; <16 kg for women). |
Baseline to 3 months.
|
|
Muscle Strength - Chair Stand Test
Periodo de tiempo: Baseline to 3 months.
|
Change in lower-limb functional strength measured by the 30-second chair stand test. The outcome is the total number of complete sit-to-stand repetitions performed within 30 seconds following standardized protocol. |
Baseline to 3 months.
|
|
Muscle Mass - Calf Circumference
Periodo de tiempo: Baseline to 3 months.
|
Change in muscle mass estimated by calf circumference (cm), measured at the widest point of the calf using a flexible tape. A value <31 cm will be considered indicative of potential muscle mass deficit. |
Baseline to 3 months.
|
|
Muscle Mass - Ultrasound of Rectus Femoris
Periodo de tiempo: Baseline to 3 months.
|
Change in quantitative and qualitative muscle parameters assessed by ultrasound of the rectus femoris (muscle thickness, cross-sectional area, and echogenicity), following validated measurement criteria for sarcopenia assessment. |
Baseline to 3 months.
|
|
Sex Differences in Response to the Exercise Prescription Program (Standardized Change Score)
Periodo de tiempo: Baseline to 3 months.
|
This outcome will assess whether biological sex modifies the effect of the intervention on functional and health-related outcomes. Sex-specific differences will be evaluated using standardized change scores (z-scores). The standardized composite score will be derived from the following previously defined outcome measures: Muscle strength (handgrip dynamometry (kg) and the 30-second chair stand test) Aerobic capacity (6-minute walk test) Muscle mass, assessed by calf circumference (cm) and ultrasound measurements of rectus femoris muscle thickness Physical activity level, (Global Physical Activity Questionnaire (GPAQ) Health-related quality of life (SF-36 questionnaire) Each variable will be standardized before aggregation to ensure comparability across different units of measurement. The resulting composite score will be compared between men and women to determine if sex influences the magnitude of response to the exercise prescription program. |
Baseline to 3 months.
|
|
Correlation Between Polypharmacy and Change in Handgrip Strength
Periodo de tiempo: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in muscle strength in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Muscle strength will be assessed by handgrip strength, measured in kilograms (kg) using a calibrated hand dynamometer. Change in handgrip strength will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Appendicular Skeletal Muscle Mass
Periodo de tiempo: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in muscle mass in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Muscle mass will be assessed as appendicular skeletal muscle mass, measured in kilograms (kg) using dual-energy X-ray absorptiometry (DXA). Change in muscle mass will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Physical Performance
Periodo de tiempo: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in physical performance in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Physical performance will be assessed using the Short Physical Performance Battery (SPPB), reported as a total score (points on a standardized scale). Change in SPPB score will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Quality of Life
Periodo de tiempo: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in quality of life in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Quality of life will be assessed using the EuroQol-5 Dimension (EQ-5D) questionnaire, reported as a standardized index score. Change in EQ-5D score will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- PREFIS-AP
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
Marco de tiempo para compartir IPD
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
Criterios de acceso compartido de IPD
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .